Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...
These differences remained significant beyond the initial 90 days, indicating durable diagnostic sensitivity and facilitating earlier, risk-appropriate treatment decisions, which supports broader ...
Bladder cancer affects more than 86,000 people in the United States each year, according to the American Cancer Society, with the majority being over age 55. And while the disease can often be ...
To reduce papillary tumor recurrence, optimized intravesical mitomycin C combined with fluorescence blue-light cystoscopy shows promise. Fluorescence blue-light cystoscopy along with optimized ...
Photocure ASA announced that The Journal of Medical Economics has published a study describing a novel health economics model developed for a Danish health technology appraisal, comparing blue light ...
Subscribe to The St. Louis American‘s free weekly newsletter for critical stories, community voices, and insights that matter. Sign up (StatePoint) Like many bladder cancer survivors, Karen S. often ...
(StatePoint) When John noticed blood in his urine, he consulted his doctor and was quickly referred to a urologist. (John is a composite character, based on the experiences of real-life patients.) ...
EL SEGUNDO, Calif.--(BUSINESS WIRE)--The KARL STORZ Photodynamic Diagnosis (PDD) System - Blue Light Cystoscopy with Cysview (BLCC) is one of the medical innovations that was showcased in front of ...
Photocure ASA reported new real-world data presented at the American Urological Association 2026 congress showing that Blue Light Cystoscopy significantly improves early detection of carcinoma in situ ...
Neoadjuvant gemcitabine and carboplatin followed by immediate radical cystectomy for muscle-invasive bladder cancer patients ineligible for cisplatin-based chemotherapy: A propensity score-matched ...
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the presentation of two Photocure-supported abstracts at the American Urological Association ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results